On October 19, 2022, the FDA amended the Emergency Use Authorization (EUA) for the Novavax COVID-19 Vaccine, Adjuvanted. The EUA now authorizes a first booster dose for patients 18 years and older:
- For whom an FDA-authorized bivalent (updated) booster isn’t accessible or clinically appropriate
- Who choose to get the Novavax booster because they wouldn’t otherwise get a COVID-19 booster
Use code 0044A for Novavax Covid-19 Vaccine, Adjuvanted - Administration - Booster Dose. The code description is:
- CPT Code 0044A – Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; booster dose
Resources:
Novavax COVID-19 Vaccine, Adjuvanted EUA
CMS COVID-19 Vaccines and Monoclonal Antibodies Toolkit